AgomAb Therapeutics N.V. American Depositary Shares (AGMB) Stock Overview
Explore AgomAb Therapeutics N.V. American Depositary Shares’s financial performance, market position, analyst ratings, and future outlook.
AgomAb Therapeutics N.V. American Depositary Shares (AGMB)
Key Financials
Key Financials
Market Cap
614.6M
P/E Ratio
-8.94
EPS (TTM)
$-46.11
ROE
-0.46%
AGMB Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of AgomAb Therapeutics N.V. American Depositary Shares (NASDAQ: AGMB) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, AgomAb Therapeutics N.V. American Depositary Shares's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of AGMB on the NASDAQ shows an RSI of 51.81, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $7.64 for the NASDAQ listing.
Key metrics behind AgomAb Therapeutics N.V. American Depositary Shares's NASDAQ-traded stock include a P/E ratio of -8.94 and a market capitalization of 614.6M. Combined with our AI analysis, these give both institutional and retail investors a clear view of AGMB on the NASDAQ.